SA
Log In
ENTA
OverviewIntelligenceChart

Analyst Sentiment

Wall St. Consensus
Buy
16 analysts·Moderate coverage
69
Score
14 Buy (88%)0 Hold (0%)2 Sell (12%)
Rating Breakdown
Strong Buy
00%
Buy
1488%
Hold
00%
Sell
213%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$20.00
+38.1%
Consensus
$54.00
+272.9%
Bull
$87.00
+500.8%
12-Month Target Range16 analysts
$20.00$54.00$87.00
Current $14.48Consensus
Current Price
$14.48
Upside to Consensus
$39.52

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev-3.18%
EPS—
FY2028
Rev+4.96%
EPS—
FY2029
Rev+5.74%
EPS—

Earnings Surprises

Recent Analyst Actions

Oct 1, 2025Jefferies
Enanta upgraded to Buy from Hold at Jefferies
Target:$20.00
+83.7%from $10.88
Jun 3, 2025JMP Securities
Enanta price target raised to $24 from $23 at Citizens JMP
Target:$24.00
+233.8%from $7.19
Dec 9, 2022H.C. Wainwright
HC Wainwright & Co. Initiates Coverage On Enanta Pharmaceuticals with Buy Rating, Announces Price Target of $56
Target:$56.00
+33.5%from $41.96
Nov 22, 2022RBC Capital
RBC Capital Maintains Sector Perform on Enanta Pharmaceuticals, Lowers Price Target to $54
Target:$54.00
+16.4%from $46.40
Jul 29, 2022Piper Sandler
Enanta's 'strong' EDP-235 data supports 'impressive' profile, says Piper Sandler
Target:$87.00
+69.7%from $51.27

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance